Meet your clinical, economic, and regulatory needs throughout a product's lifecycle
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreYour world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreFor government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MOREThe transformation of the Medical Affairs function in the healthcare industry has been a popular topic over the past decade. Medical Affairs is indisputably a 'strategic pillar' throughout the product lifecycle, and recent needed updates within the healthcare environment have pushed this transformation even further into the world of patient-centricity.
The impact on the Medical Affairs profession is pronounced as patient centricity is its mission and practitioners are most often responsible for incorporating non-registrational real world data (RWD), including development of an RWE strategy, into an overarching evidence generation plan to ensure that patient safety and product efficacy are balanced. In this article, the authors will review the scope and emerging importance of RWE, the responsibility of Medical Affairs in the RWE strategy and layout the three key steps to developing a RWE roadmap.
Meet your clinical, economic, and regulatory needs throughout a product's lifecycle